Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our market websites.
-
GSK and Theravance announce completion of the Relovair™* registrational programme and topline results from Relovair™ vs. Advair® phase III studies in COPD
GSK and Theravance, Inc. today announced the registrational programme for Relovair™ is now complete. In addition, results from two studies for the once-daily investigation...
Read more -
GSK confirms significant investments in UK manufacturing: Ulverston in Cumbria selected as site of new biopharmaceutical factory
GSK today confirmed that it will invest more than £500m in the UK across its manufacturing sites to increase production of key active ingredients for its pharmaceutical pro...
Read more -
GSK announces positive vote from FDA panel for pazopanib in certain advanced soft tissue sarcomas
GSK announced today that the Oncologic Drugs Advisory Committee (ODAC) to the US FDA voted 11 to 2 that evidence from clinical studies support a favourable benefit; risk assessm...
Read more -
GlaxoSmithKline provides further update on divestment of non-core over-the-counter (OTC) brands
In February 2011, GSK announced its intention to divest non-core Consumer Healthcare OTC products predominantly in the United States and Europe with aggregate sales of approxima...
Read more -
GSK reinforces commitment to youth training with launch of new UK apprenticeship programme
GSK today announced the launch of a new multi-disciplinary apprenticeship scheme. The programme, which will sit alongside GSK's established graduate and undergraduate recruitmen...
Read more -
Regulatory Update: GSK announces submissions for two influenza vaccines
GlaxoSmithKline [GSK] announced today that it has submitted regulatory files for two of its influenza vaccines currently in development.
Read more -
Innovative UK research project to study the value medicines bring to patients in the real world
Unique collaboration to ensure medicines under development meet patient and healthcare system needs.
Read more -
GSK and Daiichi Sankyo vaccines joint venture to become largest vaccines company in Japan
GlaxoSmithKline (GSK) today announced that it has signed an agreement with Daiichi Sankyo Co., Ltd. to form a Joint Venture (JV) which is expected to create the number one vacci...
Read more -
GlaxoSmithKline receives positive opinion in Europe from the CHMP for Nimenrix®
GSK announced that the EMA's Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorisation for Nimenrix® for active...
Read more -
EU and US Regulatory Update – Tykerb/Tyverb® (lapatinib)
GlaxoSmithKline announced today that it has submitted regulatory applications in Europe and the US related to Tykerb/ Tyverb (lapatinib) and its use in combination with trastuzu...
Read more -
GSK results announcement for Q4 and full year 2011
GSK delivers continued underlying sales growth*, R&D progress and improving financial returns to shareholders
Read more -
GSK joins new global partnership to help defeat ten neglected tropical diseases by 2020
GSK today announced it has joined other global pharmaceutical companies and leading organisations including the WHO, the Bill & Melinda Gates Foundation, the UK Department f...
Read more -
GSK announces changes to the Board
GlaxoSmithKline plc today announced that at the company’s Annual General Meeting (AGM) in 2013, following nine years of respective service to the GSK Board, Sir Crispin Da...
Read more -
GSK responds to the recent court ruling on the COMPAS study in Mendoza, Argentina
GlaxoSmithKline respectfully disagrees with the recent court ruling in favour of the ANMAT on the fine issued to GSK regarding the administrative conduct of the COMPAS study in ...
Read more -
GSK and Theravance announce initial outcomes from pivotal Phase III studies for once-daily Relovair™* in COPD and asthma
GSK and Theravance, Inc. today announced the completion of the phase III registration programme for the once-daily investigational medicine Relovair™* in patients with COP...
Read more -
GlaxoSmithKline provides update on divestment of non-core over-the-counter (OTC) brands
Agreement reached to divest brands in USA and Canada to Prestige Brands Holdings, Inc. for £426m ($660m). Process continues for divesting brands outside these markets and global...
Read more -
GSK extends pneumococcal vaccine agreement with GAVI Alliance
GSK today announced it has expanded its agreement with the GAVI Alliance in a move to help protect millions more children in the world's poorest countries from pneumococcal...
Read more -
GlaxoSmithKline and Human Genome Sciences initiate phase III trial of belimumab (Benlysta®) administered subcutaneously in subjects with systemic lupus erythematosus
GlaxoSmithKline (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that dosing has been initiated in BLISS-SC, a new Phase III trialto evaluate the efficacy, s...
Read more -
GSK presents phase lll data for lapatinib at San Antonio breast cancer symposium
Improvement in disease-free survival does not reach statistical significance in study of delayed adjuvant therapy with lapatinib (Tykerb or Tyverb) monotherapy in HER2 positive ...
Read more -
GSK and Help for Heroes partner to support the rehabilitation of wounded servicemen and women in the UK
GSK and Help for Heroes today announced a new partnership to help support injured British armed forces personnel successfully transition back into civilian life. The partnership...
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday healthcare products to medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines and consumer healthcare from inside and outside our labs.
